Abstract
Migraine is a benign self-limiting condition for which the objective of treatment is to maximize the patient’s quality of life by reducing the frequency of attacks and attenuating the pain and suffering of an individual attack as quickly and safely as possible. Evaluating the efficacy of antimigraine treatments, particularly those for the management of the acute attack, is relatively easy because acute symptomatic benefit is the criterion of success. For prophylaxis, therapeutic success generally is measured by relatively simple parameters such as attack frequency. Given that the clinical response to antimigraine therapies relatively is readily assessed by history, the role of more sophisticated investigations such as pharmacokinetic studies may not be immediately clear. This paper aims to provide clinicians with a guide to interpretation of such studies.
Similar content being viewed by others
References and Recommended Reading
Perry CM, Markham A: Sumatriptan: an updated review of its use in migraine. Drugs 1998, 55:889–922.
Visser WH, Burggraaf J, Muller LM, et al.: Pharmacokinetic and pharmacodynamic profiles of sumatriptan in migraine patients with headache recurrence or no response. Clin Pharmacol Ther 1996, 60:452–460. This is one of the key papers showing that important clinical efficacy differences between patients are not caused by pharmacokinetic differences, emphasizing caution in extrapolating clinical endpoint from pharmacokinetics.
Maassen van den Brink A, Vergouwe MN, Ophoff RA, et al.: 5-HT1B receptor polymorphism and clinical response to sumatriptan. Headache 1998, 38:288–291.
Gruffyd-Jones K, Kies B, Middleton A, et al.: Zolmitriptan versus sumatriptan for the acute oral treatment of migraine: a randomized, double-blind, international study. Eur J Neurol 2001, 8:237–245.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Rolan, P. Pharmacokinetic studies in migraine: What questions should physicians ask?. Current Science Inc 8, 219–222 (2004). https://doi.org/10.1007/s11916-004-0055-3
Issue Date:
DOI: https://doi.org/10.1007/s11916-004-0055-3